-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

Benzinga·08/11/2026 13:09:06
Listen to the news
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.